|
A Benzimidazole derivative
M. O. A.:
It decreases gastric acid secretion by inhibiting gastric H+ K+ -ATPase.
P/K:
It is a pro-drug, and is activated to sulphonamide derivatives. After absorption, the drug is extensively metabolized in liver.
On set of action: 1-2 hours
Duration of action: About 24 hours
Adverse Effects:
Nausea, vomiting, constipation, epigastric distress, dyspepsia, skinrash, utricaria, pruritis, arthralgia, depression and peripheral edema.
Contraindication: Hypersensitivity
Special Precautions:
Hepatic failure and possibility of gastric malignancy to be excluded. Capsule is not to be crushed or chewed. It is to be swallowed as whole along with water.
Interactions:
Antacids: Bioavailability of Lansoprazole reduced.
Oral contraceptives, Phenytoin, Theophylline and Warferin: Caution should be exercised while using these drugs which are metabolised by the liver since Lansoprazole is a weak inducer of P450 cytochrome.
Indications:
Healing of duodenal ulcer, benign gastric ulcer, reflux oesophagitis, and benign peptic lesions unresponsive to H2 receptor antagonists and Zollinger Ellison syndrome.
Dosage:
Adults: Benign gastric ulcer, duodenum: 30 mg daily in the morning for 4-8 weeks. Reflux oesophagitis: 30 mg daily in the morning for 4-8 weeks. Maintenance 15-30 mg. Daily
Children: Not recommended.
|
